vs

Side-by-side financial comparison of ACRES Commercial Realty Corp. (ACR) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

InfuSystem Holdings, Inc is the larger business by last-quarter revenue ($36.2M vs $20.0M, roughly 1.8× ACRES Commercial Realty Corp.). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -6.5%). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs 3.3%).

Piramal Realty is an Indian real estate company, founded in 2012 and headquartered in Mumbai, India. It is a part of the Piramal Group. The company focuses on the development of residential and commercial properties, with projects under development covering an estimated 15 million square feet. Among its notable projects include Piramal Aranya, Piramal Mahalaxmi, Piramal Revanta, Piramal Vaikunth and Piramal Agastya.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

ACR vs INFU — Head-to-Head

Bigger by revenue
INFU
INFU
1.8× larger
INFU
$36.2M
$20.0M
ACR
Growing faster (revenue YoY)
INFU
INFU
+13.6% gap
INFU
7.0%
-6.5%
ACR
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
3.3%
ACR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACR
ACR
INFU
INFU
Revenue
$20.0M
$36.2M
Net Profit
$6.3M
Gross Margin
56.4%
Operating Margin
30.8%
10.3%
Net Margin
31.6%
Revenue YoY
-6.5%
7.0%
Net Profit YoY
-32.0%
EPS (diluted)
$-0.41
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACR
ACR
INFU
INFU
Q4 25
$20.0M
$36.2M
Q3 25
$21.0M
$36.5M
Q2 25
$21.9M
$36.0M
Q1 25
$17.0M
$34.7M
Q4 24
$21.4M
$33.8M
Q3 24
$22.4M
$35.3M
Q2 24
$20.9M
$33.7M
Q1 24
$18.8M
$32.0M
Net Profit
ACR
ACR
INFU
INFU
Q4 25
$6.3M
Q3 25
$18.0M
$2.3M
Q2 25
$4.3M
$2.6M
Q1 25
$-730.0K
$-267.0K
Q4 24
$9.3M
Q3 24
$8.1M
$1.8M
Q2 24
$6.4M
$717.0K
Q1 24
$4.9M
$-1.1M
Gross Margin
ACR
ACR
INFU
INFU
Q4 25
56.4%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
53.8%
Q3 24
53.9%
Q2 24
49.5%
Q1 24
51.5%
Operating Margin
ACR
ACR
INFU
INFU
Q4 25
30.8%
10.3%
Q3 25
85.8%
10.4%
Q2 25
19.8%
10.5%
Q1 25
-3.8%
1.8%
Q4 24
43.4%
7.7%
Q3 24
36.4%
9.2%
Q2 24
30.8%
5.5%
Q1 24
26.2%
-2.6%
Net Margin
ACR
ACR
INFU
INFU
Q4 25
31.6%
Q3 25
85.8%
6.2%
Q2 25
19.8%
7.2%
Q1 25
-4.3%
-0.8%
Q4 24
43.5%
Q3 24
36.0%
5.1%
Q2 24
30.6%
2.1%
Q1 24
26.2%
-3.5%
EPS (diluted)
ACR
ACR
INFU
INFU
Q4 25
$-0.41
$0.09
Q3 25
$1.34
$0.11
Q2 25
$-0.10
$0.12
Q1 25
$-0.80
$-0.01
Q4 24
$0.51
$0.05
Q3 24
$0.36
$0.08
Q2 24
$0.21
$0.03
Q1 24
$0.07
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACR
ACR
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$83.8M
$3.2M
Total DebtLower is stronger
$1.6B
$19.6M
Stockholders' EquityBook value
$420.8M
$57.3M
Total Assets
$2.2B
$100.6M
Debt / EquityLower = less leverage
3.68×
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACR
ACR
INFU
INFU
Q4 25
$83.8M
$3.2M
Q3 25
$40.9M
$955.0K
Q2 25
$42.7M
$720.0K
Q1 25
$66.0M
$1.5M
Q4 24
$56.7M
$527.0K
Q3 24
$70.1M
$380.0K
Q2 24
$89.6M
$146.0K
Q1 24
$84.6M
$822.0K
Total Debt
ACR
ACR
INFU
INFU
Q4 25
$1.6B
$19.6M
Q3 25
$1.2B
$20.9M
Q2 25
$1.3B
$26.3M
Q1 25
$1.3B
$28.7M
Q4 24
$1.4B
$23.9M
Q3 24
$1.5B
$28.0M
Q2 24
$1.6B
$34.2M
Q1 24
$1.6B
$29.9M
Stockholders' Equity
ACR
ACR
INFU
INFU
Q4 25
$420.8M
$57.3M
Q3 25
$432.9M
$55.5M
Q2 25
$425.3M
$54.5M
Q1 25
$430.1M
$55.1M
Q4 24
$439.1M
$57.5M
Q3 24
$436.3M
$55.5M
Q2 24
$434.0M
$53.5M
Q1 24
$432.8M
$52.3M
Total Assets
ACR
ACR
INFU
INFU
Q4 25
$2.2B
$100.6M
Q3 25
$1.7B
$98.9M
Q2 25
$1.8B
$100.8M
Q1 25
$1.8B
$104.3M
Q4 24
$1.9B
$103.6M
Q3 24
$2.0B
$105.3M
Q2 24
$2.1B
$108.5M
Q1 24
$2.1B
$104.8M
Debt / Equity
ACR
ACR
INFU
INFU
Q4 25
3.68×
0.34×
Q3 25
2.76×
0.38×
Q2 25
3.10×
0.48×
Q1 25
2.97×
0.52×
Q4 24
3.12×
0.41×
Q3 24
3.43×
0.50×
Q2 24
3.67×
0.64×
Q1 24
3.79×
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACR
ACR
INFU
INFU
Operating Cash FlowLast quarter
$4.1M
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
0.65×
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACR
ACR
INFU
INFU
Q4 25
$4.1M
$7.1M
Q3 25
$-9.4M
$8.5M
Q2 25
$11.8M
$7.0M
Q1 25
$-4.6M
$1.8M
Q4 24
$19.4M
$7.9M
Q3 24
$8.4M
$9.8M
Q2 24
$6.9M
$2.3M
Q1 24
$3.3M
$377.0K
Free Cash Flow
ACR
ACR
INFU
INFU
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$1.6M
Q4 24
$7.4M
Q3 24
$9.8M
Q2 24
$2.0M
Q1 24
$195.0K
FCF Margin
ACR
ACR
INFU
INFU
Q4 25
19.3%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
4.7%
Q4 24
21.9%
Q3 24
27.7%
Q2 24
5.9%
Q1 24
0.6%
Capex Intensity
ACR
ACR
INFU
INFU
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
0.4%
Q4 24
1.6%
Q3 24
0.1%
Q2 24
1.0%
Q1 24
0.6%
Cash Conversion
ACR
ACR
INFU
INFU
Q4 25
0.65×
Q3 25
-0.52×
3.76×
Q2 25
2.72×
2.70×
Q1 25
Q4 24
2.08×
Q3 24
1.05×
5.45×
Q2 24
1.07×
3.22×
Q1 24
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACR
ACR

Other$10.8M54%
Pacmulti JVLLC$5.2M26%
Mccallum Jv Llc$2.5M12%
Office Complex$1.5M7%

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons